GlassScriptPhysician profile
Amy Loden
NPI 1417189564
$4,099.50
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $859 · 2021: $1,729 · 2022: $382 · 2023: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $938.45 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $672.48 | 2019-2023 | |
| Allergan, INC. | $287.45 | 2019-2020 | |
| Lilly USA, LLC | $242.55 | 2019-2023 | Mounjaro, Trulicity |
| Biohaven Pharmaceuticals, INC. | $228.39 | 2021 | |
| Amgen INC. | $225.39 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.40 | 2020-2023 | Xifaxan |
| Coopersurgical, INC. | $185.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $175.65 | 2019-2022 | |
| Daiichi Sankyo INC. | $129.67 | 2019-2020 | |
| Ucb, INC. | $90.00 | 2021 | |
| Amag Pharmaceuticals, INC. | $68.14 | 2019-2020 | |
| Eisai INC. | $66.85 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $58.83 | 2022 | |
| Therapeuticsmd, INC. | $50.09 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $49.59 | 2019-2021 | |
| Pfizer INC. | $46.49 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $41.19 | 2021 | |
| Sage Therapeutics, LLC | $29.97 | 2020-2021 | |
| Ethicon US, LLC | $29.65 | 2019 | |
| Currax Pharmaceuticals LLC | $27.99 | 2021-2023 | Contrave |
| Duchesnay USA Incorporated | $23.14 | 2019 | |
| Endo Pharmaceuticals INC. | $20.70 | 2022 | |
| Exact Sciences Corporation | $19.02 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $18.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.12 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $16.24 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.75 | 2021 | |
| Corcept Therapeutics | $14.41 | 2022 | |
| Astellas Pharma US INC | $13.81 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $13.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.79 | 2022 | |
| Agile Therapeutics, INC. | $12.04 | 2021 | |
| Lupin INC. | $11.55 | 2019 | |
| Boston Scientific Corporation | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Loden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.